Terminated PHASE4 INTERVENTIONAL NCT00216424

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma

Sponsor: Hoffmann-La Roche

Conditions Colorectal Cancer

Interventions Capecitabine (Xeloda)

Updated 5 times since 2017 Last updated: Nov 9, 2007 Started: Feb 28, 2005 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of accrual

Other terminated trials from Hoffmann-La Roche

See all terminations from Hoffmann-La Roche

Other Colorectal Cancer trials with similar outcome

Browse all Colorectal Cancer trials

A PHASE4 clinical study on Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Hoffmann-La Roche and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
James A. Haley Veterans Administration Hospital

Data source: James A. Haley Veterans Administration Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States